{"id":"capecitabine-combined-with-pyrotinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Myelosuppression"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_fixedAt":"2026-03-30T13:26:10.847250","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets cancer cells through dual mechanisms: capecitabine disrupts DNA synthesis by inhibiting thymidylate synthase, while pyrotinib irreversibly inhibits multiple HER family receptor tyrosine kinases. Together, they provide complementary cytotoxic and targeted inhibition of HER-driven proliferation pathways, particularly effective in HER2-positive cancers.","oneSentence":"Capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, while pyrotinib is a pan-HER tyrosine kinase inhibitor that blocks HER1, HER2, and HER4 signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:49.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer"},{"name":"HER2-positive gastric cancer"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT05424835","phase":"PHASE3","title":"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-08-04","conditions":"HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","enrollment":381},{"nctId":"NCT06208410","phase":"PHASE1, PHASE2","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2024-01-11","conditions":"Advanced Solid Tumors","enrollment":306},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT07019337","phase":"PHASE2","title":"Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-30","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer","enrollment":100},{"nctId":"NCT06754059","phase":"","title":"Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC","status":"RECRUITING","sponsor":"zhangjie","startDate":"2021-06-01","conditions":"HER2-positive Breast Cancer","enrollment":60},{"nctId":"NCT06483386","phase":"PHASE2","title":"Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-15","conditions":"Breast Cancer","enrollment":109},{"nctId":"NCT06481553","phase":"","title":"RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-02-01","conditions":"Breast Cancer Stage IV","enrollment":480},{"nctId":"NCT06217185","phase":"PHASE4","title":"The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-01-02","conditions":"HER2-positive Breast Cancer, Advanced Breast Cancer","enrollment":100},{"nctId":"NCT05575804","phase":"PHASE1, PHASE2","title":"GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-10-01","conditions":"Advanced/ Metastatic Her-2 Positive Breast Cancer","enrollment":75},{"nctId":"NCT05042791","phase":"PHASE2","title":"A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases","status":"UNKNOWN","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2022-03-01","conditions":"HER2-positive Metastatic Breast Cancer","enrollment":362},{"nctId":"NCT06152822","phase":"PHASE2","title":"Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2023-11-30","conditions":"Breast Cancer With Brain Metastases","enrollment":30},{"nctId":"NCT06035016","phase":"","title":"Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-06-01","conditions":"HER2-positive Breast Cancer, Early-stage Breast Cancer","enrollment":300},{"nctId":"NCT04582968","phase":"PHASE1, PHASE2","title":"Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-01-02","conditions":"Breast Cancer, Brain Metastases, HER2-positive Breast Cancer","enrollment":39},{"nctId":"NCT04001621","phase":"PHASE2","title":"Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-06-26","conditions":"Metastatic Breast Cancer","enrollment":100},{"nctId":"NCT05359120","phase":"","title":"Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-30","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT03805399","phase":"PHASE1, PHASE2","title":"FUSCC Refractory TNBC Umbrella (FUTURE)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-10-18","conditions":"Triple-negative Breast Cancer","enrollment":140},{"nctId":"NCT04355858","phase":"PHASE2","title":"Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-05-01","conditions":"Breast Cancer, Metastatic Cancer","enrollment":319},{"nctId":"NCT04769050","phase":"","title":"Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-02-18","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT05292742","phase":"PHASE2","title":"Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2021-07-02","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":206},{"nctId":"NCT05255523","phase":"PHASE2","title":"Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University Union Hospital","startDate":"2022-02-20","conditions":"Advanced Breast Cancer","enrollment":60},{"nctId":"NCT05111444","phase":"PHASE2","title":"Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-12-31","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":65},{"nctId":"NCT04681911","phase":"PHASE2","title":"Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-09-09","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT04646759","phase":"PHASE3","title":"Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-10-14","conditions":"Breast Cancer","enrollment":516},{"nctId":"NCT04227041","phase":"PHASE1, PHASE2","title":"A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer","status":"UNKNOWN","sponsor":"Qingdao Zhixin Health Technology Co., Ltd.","startDate":"2020-01-10","conditions":"HER-2 Positive Colorectal Cancer","enrollment":34},{"nctId":"NCT04095390","phase":"PHASE2","title":"A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer","status":"UNKNOWN","sponsor":"Jinming Yu","startDate":"2019-09-30","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":60},{"nctId":"NCT03923166","phase":"PHASE2","title":"Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-04-19","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT02361112","phase":"PHASE1","title":"Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2014-08","conditions":"Metastatic Breast Cancer","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["xeloda combined with Pyrotinib"],"phase":"phase_3","status":"active","brandName":"Capecitabine combined with Pyrotinib","genericName":"Capecitabine combined with Pyrotinib","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, while pyrotinib is a pan-HER tyrosine kinase inhibitor that blocks HER1, HER2, and HER4 signaling. Used for HER2-positive metastatic breast cancer, HER2-positive gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}